At a glance
- Originator Hebrew University of Jerusalem; The Hospital for Sick Children; University of Toronto
- Developer Friedrich-Alexander-University Erlangen-Nuremberg; Hebrew University of Jerusalem; The Hospital for Sick Children; University of Toronto; Yissum Research Development Company
- Class Antineoplastics; Tyrphostins
- Mechanism of Action Janus kinase-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
- 21 Sep 1999 SUGEN has been acquired by Pharmacia & Upjohn
- 20 Aug 1998 Preclinical development for Multiple myeloma in Germany (Unknown route)